

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.elsevier.com/locate/ihj](http://www.elsevier.com/locate/ihj)

## Original Article

# Spectrum of acute coronary syndrome in North Eastern India – A study from a major center

Farhin Iqbal<sup>a,\*</sup>, J.C. Barkataki<sup>b</sup><sup>a</sup> Assistant Professor, Department of Cardiology, Gauhati Medical College, Guwahati, India<sup>b</sup> Professor, Department of Cardiology, Gauhati Medical College, Guwahati, India

## ARTICLE INFO

## Article history:

Received 22 August 2014

Accepted 21 July 2015

Available online 18 January 2016

## Keywords:

Acute coronary syndrome

North Eastern India

Clinical spectrum

## ABSTRACT

**Aim:** Spectrum of acute coronary syndrome (ACS) has not been reported from North Eastern India. The present study was undertaken to study the clinical spectrum of ACS.

**Methods:** We prospectively collected data of 704 ACS patients from February 2011 to August 2012 in Gauhati Medical College, a tertiary care center. We evaluated data on clinical characteristic, treatment, and outcome in ACS patients.

**Results:** Of the 704 ACS patients, 72.4% presented with STEMI and 27.6% presented with NSTEMI/UA. Mean age of presentation was 56.5 years. Mean time to presentation was 11.42 h and was higher in NSTEMI/UA than STEMI (12.86 h vs. 9.98 h,  $p < 0.001$ ). Treatment for STEMI did not differ much from NSTEMI/UA with  $\geq 90\%$  of patients in both groups receiving antiplatelets, statin, and anticoagulants. 39% of STEMI received thrombolytic therapy and percutaneous coronary intervention (PCI) rates were higher in STEMI. The 30-day mortality was found to be 10.22%, with STEMI having higher mortality than NSTEMI/UA (11.76% vs. 6.18%,  $p = 0.03$ ).

**Conclusion:** These data represent the first reported study on spectrum of ACS in North Eastern India and has noted few key differences from the national registry CREATE, with greater percentage of STEMI patients, greater delay in seeking treatment, greater 30-day mortality, and lesser percentage of patients receiving reperfusion therapy.

© 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

## 1. Introduction

CREATE, the national registry on Indian patients with ACS, has shown that the pattern of ACS among Indians is much different from that of the Western populations [1].

The clinical spectrum of ACS is not studied in North Eastern India.

The present study was undertaken in Gauhati Medical College, a tertiary care hospital with the aim of studying the clinical presentation of the wide spectrum of ACS.

\* Corresponding author.

E-mail addresses: [farhiniqbal@rediffmail.com](mailto:farhiniqbal@rediffmail.com), [farhiniqbal@gmail.com](mailto:farhiniqbal@gmail.com) (F. Iqbal).<http://dx.doi.org/10.1016/j.ihj.2015.07.040>

0019-4832/© 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

## 2. Methods

All patients presenting with ACS from February 2011 to August 2012 in the emergency room (ER) were included in the study. Detailed history, physical examination, and necessary investigations were done in all patients.

### Inclusion criteria

1. Patients must be greater than 18 years of age.
2. Patients must fulfill the diagnostic criteria of ACS as given below:

Diagnosis of myocardial infarction was made if there is: Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following: [2]

- (a) Ischemic symptoms;
- (b) Development of pathologic Q waves on the ECG;
- (c) ECG changes indicative of ischemia (ST segment elevation or depression).

Cases of ischemic symptoms with elevation of ST segment in electrocardiographic (ECG) leads/presumed new onset left bundle branch block in ECG were categorized as STEMI. Cases of ischemic symptoms without ST segment elevation were categorized as NSTEMI if their cardiac biomarkers are positive.

Unstable Angina (UA) was defined as angina pectoris (or equivalent type of ischemic discomfort) with at least one of three features:

- (1) occurring at rest (or minimal exertion) and usually lasting >20 min (if not interrupted by nitroglycerin administration);
  - (2) being severe and described as frank pain, and of new onset (i.e., within 1 month; and
  - (3) occurring with a crescendo pattern (i.e., more severe, prolonged, or frequent than previously).
  - (4) Patients with above features without elevation in cardiac markers were categorized as UA [3].
3. Written consent must be given

### Exclusion criteria

1. Patients who were initially treated elsewhere and referred to the study center only for additional management;
2. Patients with proven non-cardiac chest pain and
3. Patients who were discharged before completion of the treatment for any reasons.

The baseline clinical characteristics, which were analyzed, were the age, gender, hypertension, diabetes mellitus, smoking status, and Body mass Index (BMI).

Mode of presentation, time of occurrence of the ACS, clinical course in the hospital, time to reach hospital, time until thrombolysis, treatments in hospital, the mean duration of hospital stay, and complications related to the ACS and its

treatment were analyzed. In our study, patients were considered to have atypical presentation if they presented with dyspnea, nausea/vomiting, indigestion, fatigue, sweating, and arm or shoulder pain as presenting symptoms in the absence of chest pain.

The in-hospital outcome was analyzed. Those patients giving consent for angiography were taken up for angiography. Angiographic findings were noted. They were categorized as -

- 1, Normal coronaries; 2, insignificant disease (less than 50% diameter stenosis as per visual estimation); 3, single vessel disease; 4, double vessel disease; 5, triple vessel disease; 6, left main disease.

A comparison of clinical parameters, treatment received in hospital and outcome and angiographic profile between STEMI and NSTEMI/UA were done.

The authors certify that informed consent has been obtained from each patient and the study protocol conforms to the ethical guidelines as approved by the institution's human ethics committee.

## 3. Statistical methods

Statistical analysis was performed using the online statistical calculator, [www.graphpad.com/](http://www.graphpad.com/).

Categorical variables were compared by chi-square test and the continuous variables are presented as mean ( $\pm$ SD) and were compared by unpaired t test. A probability value of <0.05 was considered statistically significant.

## 4. Results

A total of 704 consecutive cases of ACS were included in the present study. Out of 704 patients, 510 (72.4%) presented with STEMI and 194 (27.6%) presented with NSTEMI/UA. Of the 194 patients with NSTEMI/UA, 121 (62.37%) presented with NSTEMI and 73 (37.6%) presented with UA. Males outnumbered females in STEMI, but in NSTEMI/UA, both the sexes were almost equal. Mean age of presentation was 56.5 years. The mean age of NSTEMI/UA is higher than STEMI patients (57.2 years vs. 55.8 years,  $p = 0.05$ ).

Mean time to presentation was 11.42 h and was higher in NSTEMI/UA than STEMI (12.86 h vs 9.98 h,  $p < 0.001$ ). 45.02% were smokers, 43.75% were hypertensive, 36.36% were diabetic, and 27.98% had BMI  $\geq 25$ . 24.5% of ACS presented with atypical presentation. We observed that patients with NSTEMI/UA have higher incidence of atypical presentation, higher incidence of diabetes, hypertension and high BMI, and higher mean time to presentation than STEMI (Ref Table 1).

On observing the treatment pattern, we observed that there was not much of a difference in treatment pattern between STEMI and NSTEMI/UA with high percentage in both groups of patients receiving standard medical therapy (Ref Table 1). However in STEMI, of the 510 patients, 39% patients received thrombolysis. Except 1 patient, all received streptokinase. The mean door to needle time was 30.12 min. The reasons for not administering thrombolytic therapy were the late presentation of cases in 281 (55.09%) patients, non-satisfactory ECG criteria in 12 (2.35%), and contra-indications for thrombolysis

**Table 1 – Clinical characteristic, treatment and outcome in ACS.**

ACS	Total	STEMI	NSTEMI/UA	p value
N	704	510	194	<0.001
<b>Clinical characteristic</b>				
Mean age	56.5 years	55.8 years	57.2 years	0.05
Sex (male)	436(61.93%)	336(65.8%)	100(51.5%)	0.007
Smoker	317(45.02%)	235(46.07%)	82(42.2%)	0.4
Hypertension	308(43.75%)	210(41.1%)	98(50.5%)	0.02
Diabetes	252(36.36%)	174(34.1%)	78(42.2%)	0.04
BMI ≥ 25	197(27.98%)	135(26.4%)	62(31.9%)	0.03
Mean time to presentation	11.42 h	9.98 h	12.86 h	<0.001
Atypical presentation	172(24.5%)	102(20%)	70(36.09%)	<0.001
Mean EF%	47.06%	46.34%	48.6%	0.13
<b>Treatment in hospital</b>				
Aspirin	699(99.2%)	506(99.2%)	193(99.4%)	0.70
Clopidogrel	695(98.7%)	502(98.4%)	193(99.4%)	0.46
Statins	699(99.2%)	506(99.2%)	193(99.4%)	0.70
ACEI/ARB	641(91.05%)	459(90%)	182(93.8%)	0.1
Beta blockers	633(89.9%)	456(89.4%)	177(91.23%)	0.56
LMWH	687(97.5%)	496(97.2%)	191(98.4%)	0.51
Thrombolysis	205(29.11%)	199(39%)	5(2.5%)	<0.001
PCI	90(12.78%)	75(14.7%)	15(7.7%)	0.01
<b>Outcome at 30 days</b>				
Heart failure/cardiogenic shock	87(12.3%)	65(12.7%)	22(11.3%)	0.7
Reinfarction	38(5.39%)	34(6.66%)	4(2.06%)	0.01
Cardiac arrest (resuscitated)	38(5.39%)	33(6.47%)	5(2.57%)	0.04
Stroke	3(0.4%)	3(0.58%)	0%	0.5
Death	72(10.22%)	60(11.76%)	12(6.18%)	0.03
<b>Cause of death</b>				
Pump failure	35(48.6%)	27(45%)	8(66.6%)	0.69
Asystole	10(13.8%)	10(18.51%)	0	0.06
VF	12(16.6%)	10(18.51%)	2(16.6%)	0.5
Multifactorial	15(20.83%)	13(24%)	2(16.6%)	0.25

in 6 (1.11%) patients. The PCI rates were higher with STEMI than NSTEMI/UA (14.7% vs. 7.7%,  $p = 0.01$ ). However, only 1.76% of STEMI underwent primary PCI.

The mean hospital day is  $4.98 \pm 1.41$  days. The mean hospital days in STEMI is  $5 \pm 1.43$ , whereas in NSTEMI/UA it is  $4.92 \pm 1.37$ . There is no statistical significant difference in hospital days between STEMI and NSTEMI/UA.

The 30-day mortality was found to be 10.22%. Patients with STEMI had significantly higher mortality than NSTEMI/UA (11.76% vs 6.18%,  $p = 0.03$ ). The most common cause of death is pump failure (48.6%). Out of 72 deaths, 67 occurred during index hospitalization and 5 died after being discharged (Ref. Table 1).

Coronary angiography was obtained in 46.30% and Echocardiography was obtained in 97.1% of ACS patients. We observed that STEMI patients have marginally lower ejection fraction and significant increase in incidence of single vessel disease than NSTEMI/UA, whereas NSTEMI/UA patients have greater increase in incidence of normal coronaries and also greater increase in triple vessel disease (Ref. Table 2).

## 5. Discussion

This is the first reported study on ACS from North Eastern India.

In our study, majority of ACS patients presented with STEMI. This is in contrast to Western studies, where Non-STEMI predominates in ACS [4–6]. However, predominance of STEMI patients in ACS in our study is comparable to Indian studies, which has also shown predominance of STEMI in ACS [1,7,8].

In our study, the mean age at presentation of ACS cases was 56.5 years, which is a decade earlier than western studies [4–6] and is comparable with mean age of cases from the Indian studies [1,7,8].

While analyzing the clinical characteristic between STEMI and NSTEMI/UA we observed that patients with NSTEMI/UA have higher incidence of atypical presentation, higher incidence of diabetes, hypertension and

**Table 2 – Coronary angiography in ACS.**

ACS	Total	STEMI	NSTEMI/UA	p value
N(%)	326(46.30%)	244(47.84%)	82(42.26%)	0.21
Normal	28(8.58%)	10(4.09%)	18(21.95%)	<0.001
Insignificant CAD	18(5.52%)	11(4.5%)	7(8.53%)	0.27
SVD	183(56.13%)	154(63.31%)	29(35.36%)	<0.001
DVD	61(18.71%)	49(20.08%)	12(14.63%)	0.35
TVD	21(8.28%)	14(5.73%)	13(16.6%)	0.008
Left main	9(2.76%)	6(2.45%)	3(3.65%)	0.85

high BMI, and higher mean time to presentation than STEMI. Similar observation has been made in various global registry and national registry [1,4–6].

In our study, of the 510 patients with STEMI, 39% patients received thrombolysis and 1.76% patients received Primary PCI. Very low proportions of STEMI cases in our study, when compared to other Indian studies, received reperfusion therapy [1,7,8]. Various factors could be responsible for high incidence of non-thrombolysis in our study. One of the main reasons is delayed presentation, which could be related to economic reasons, a lack of awareness of the importance of the symptoms, lack of ambulance services, and traffic congestion in the roads. In our study, only 1.76% patients received Primary PCI. The reason for low percentage of Primary PCI is that our center has very recently started Catheterization Laboratory, and we do not have dedicated technical staff for attending patients at night. Moreover, most of our patients are poor and cannot afford Primary PCI.

In our study, 30-day mortality was found to be 10.22%. Patients with STEMI had significantly higher mortality than NSTEMI/UA (11.76% vs 6.18%,  $p = 0.03$ ). The 30-day and in-hospital mortality is significantly higher compared to other studies, however similar to our study mortality in STEMI has been found to be higher compared to NSTEMI/UA in other studies [1,4–8].

On angiography, in STEMI, single vessel disease was the commonest pattern with 63.31% of patients having single vessel disease. Studies studying the pattern of CAD on angiography in STEMI have observed high incidence of Multi vessel disease in the range of 41–67% depending upon the baseline characteristics of the specific population studied [9,10]. In our study, in NSTEMI/UA, normal coronaries were found in 21.95%, insignificant CAD was observed in 8.53%, SVD in 35.36%, DVD in 14.63%, TVD in 16.6%, and left main disease in 3.65%. Contrary to our study, lesser incidence of normal coronaries and higher incidence of multivessel disease has been observed in TACTICS-TIMI 18 study [11].

## 6. Study limitation

There are certain limitations of our study. First, this is a single center study and pattern of ACS can be different in other parts of state. Second, coronary angiography was obtained in only 46.30% patients (who gave consent), so actual value could have been different, had we got all patients for coronary angiography.

## 7. Conclusion

These data represent the first reported study on spectrum of ACS in North Eastern India and has noted few key differences from national registry, CREATE with greater percentage of STEMI patients, greater delay in seeking treatment, greater 30-day mortality, and lesser percentage of patients receiving reperfusion therapy.

## Conflicts of interest

The authors have none to declare.

## REFERENCES

- Xavier D, Pais P, Devereaux PJ, et al. treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. *Lancet*. 2008;371: 1435–1442.
- The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol*. 2000;36:959–969.
- Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction-2002: Summary Article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). *Circulation*. 2002;106:1893–1900.
- Gabriel Steg P, Goldberg RJ, Gore JM, et al. Baseline Characteristics, Management Practices, and In-Hospital Outcomes of Patients Hospitalized With Acute Coronary Syndromes in the Global Registry of Acute Coronary Events (GRACE). *Am J Cardiol*. 2002;90:358–363.
- Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). *Eur Heart J*. 2002;23:1190–1201.
- Mandelzweig L, Battler A, Boyko V, et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. *Eur Heart J*. 2006. August 14.
- Mohan PP, Mathew R, Harikrishnan S, et al. Presentation, management, and outcomes of 25748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. *Eur Heart J*. 2013;34:121–129.
- Raihanathul MKJ, Sudhayakumar N, Abdul Khadar S, George R, Jayaprakash VL, Pappachan JM. The clinical spectrum of acute coronary syndromes: experience from a major center in Kerala. *J Assoc Physicians India*. 2009;57:.
- Lee JH, Park HS, Chae SC, et al. Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction. *Am J Cardiol*. 2009;104:182–189.
- Lekston A, Tajstra M, Gasior M, et al. Zembala M, Impact of multivessel coronary disease on one-year clinical outcomes and five-year mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. *Kardiol Pol*. 2011;69:336–343.
- Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001;344:1879–1887.